APSR2026-297

Yes
Late-Breaking
Submitted
Oral Presentation
AO19-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1211024-46903-APSR2026-297_Ria Christin_433700_439827.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ria Christin Lumpiach * Saiful Anwar General Hospital, East Java, Indonesia Department of Pulmonology and Respiratory Medicine, Medical faculty of Universitas Brawijaya Malang Indonesia
Ungky Agus Setyawan - Saiful Anwar General Hospital, East Java, Indonesia Department of Pulmonology and Respiratory Medicine, Medical faculty of Universitas Brawijaya Malang Indonesia
Rezki Tantular - Saiful Anwar General Hospital, East Java, Indonesia Department of Pulmonology and Respiratory Medicine, Medical faculty of Universitas Brawijaya Malang Indonesia
Muhammad Yusuf Musthafa - Ngudi Waluyo Wlingi General Hospital, East Java, Indonesia Department of Pulmonology and Respiratory Medicine Blitar Indonesia
Ani Budi Astuti - Universitas Brawijaya Department of Statistics, Mathematics and Natural Sciences faculty Malang Indonesia
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Ria
Christin Lumpiach
riachristinn@gmail.com
+6285343231845
31-40
Indonesia
Original Research
The Relationship Between Hypoxia Inducible Factor 1-Alpha and Vascular Endothelial Growth Factor During Chemotherapy and the Association with Treatment Response in Lung Cancer.
Maximum 25 words
Abstract Content
The hypoxic tumor microenvironment in lung cancer plays a crucial role in cancer progression. Increased activation of Hypoxia-Inducible Factor-1 alpha (HIF-1α), which increases Vascular Endothelial Growth Factor (VEGF) expression, is associated with the prognosis of lung cancer patients. However, the clinical significance of dynamic changes in circulating HIF-1 α and VEGF during chemotherapy remains unclear.
A prospective cohort analytical observational study with longitudinal design was conducted in lung cancer patients undergoing platinum based chemotherapy at Saiful Anwar General Hospital. Serum HIF-1α and VEGF levels were measured before and after three cycles of platinum base chemotherapy. Treatment response was assessed based on RECIST 1.1 criteria. Comparative data analysis used the Independent T-test, while correlative analysis used the Pearson/ Spearman correlation test and multivariate analysis used logistic regression.
An analysis of 33 patients showed a significant difference in pre- and post-chemotherapy HIF-1α levels between the two response groups (ΔHIF-1α: PD = 36.66 ± 49.49 vs. Non-PD = −79.68 ± 105.77; p < 0.001). There was no significant difference in pre- and post-chemotherapy VEGF levels between the two response groups (ΔVEGF: PD = −799.18 ± 983.86 vs. Non-PD = −339.09 ± 949.95; p = 0.246). However, changes in HIF-1α levels showed a significant negative correlation with treatment response according to RECIST 1.1 (r = −0.535; p = 0.001), and the combined HIF-1α and VEGF levels were not associated with lung cancer progression (OR = 0.99; p = 0.159).
Changes in serum HIF-1α levels after three cycles of platinum-based chemotherapy were significantly associated with treatment response based on RECIST 1.1 criteria, whereas VEGF levels were not significantly associated. These findings suggest that HIF-1α may serve as a potential biomarker for evaluating chemotherapy response in lung cancer.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Hypoxia-Inducible Factor 1 alpha Subunit, Vascular Endothelial Growth Factors, RECIST
maximum 3 keywords and no abbreviations, separated by commas
-
284